Significant predictors for topiramate pharmacokinetics: a systematic review of population pharmacokinetic studies
- 22 March 2022
- journal article
- review article
- Published by Wiley in Journal of Pharmacy Practice and Research
- Vol. 52 (2) , 94-107
Abstract
Background: Topiramate (TPM) is a second‐generation antiepileptic drug with a good pharmacokinetic profile; nonetheless, several factors such as age, renal function and concomitant medications have been reported to affect TPM clearance and dosage adjustments are necessary. Several population pharmacokinetic studies of TPM were developed and the results were partially inconsistent, with different predictors for TPM pharmacokinetic parameters and different structural models. Thus, we aimed to systematically summarise clinically significant covariates influencing TPM pharmacokinetics and clinical responses.Methods: PubMed, CINAHL Complete, Science Direct and SCOPUS databases were systematically searched from the date of their inception to May 2021. Studies conducted in humans employing a nonlinear mixed‐effects approach were included in this review. Information from retrieved articles were independently extracted using the prespecified data abstraction form.Results: Ten studies were included and most of them characterised TPM pharmacokinetics with a linear one‐compartment model. The estimated TPM clearance without covariate effects ranged from 1.15 to 2.25 L/h. Significant predictors for TPM clearance included concomitant medications, weight, age, creatinine clearance and TPM daily dose. Moreover, two studies reported the effect of TPM exposure on cognitive function, with limitations on the generalisability.Conclusions: Significant predictors for TPM clearance that are essential for individualising dosage regimens were concomitant medications, weight, age, creatinine clearance and TPM daily dose. High TPM levels had negative impacts on verbal fluency, working memory, attention and psychomotor speed; however, future studies with broader population characteristics are needed to increase generalisability.Keywords
This publication has 38 references indexed in Scilit:
- Pharmacokinetic–pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to <10 years of ageEpilepsia, 2010
- Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic StrategiesEpilepsia, 2008
- Cognitive and psychiatric effects of topiramate monotherapy in migraine treatment: an open studyEuropean Journal of Neurology, 2008
- Overview of model‐building strategies in population PK/PD analyses: 2002–2004 literature surveyBritish Journal of Clinical Pharmacology, 2007
- TopiramateDrugs, 2007
- Are Population Pharmacokinetic and/or Pharmacodynamic Models Adequately Evaluated?Clinical Pharmacokinetics, 2007
- Normative Symbol Digit Modalities Test performance in a community-based sampleArchives of Clinical Neuropsychology, 2006
- Clinical Pharmacokinetics of New-Generation Antiepileptic Drugs at the Extremes of AgeClinical Pharmacokinetics, 2006
- Topiramate Pharmacokinetics in Children and Adults with EpilepsyClinical Pharmacokinetics, 2005
- Some observations on the quantitative anatomy of the kidneyThe Journal of Pathology, 1973